[ad_1]
Roughly 17 million Americans have received the Johnson & Johnson Covid vaccine, but it will later be said to be the least protective of the options in the United States. But new data shows that the vaccine now prevents infections.hospitalizations and deaths, at least as well as Pfizer-BioNTech and Moderna vaccines.
The reasons are unclear, and not all experts are convinced that the vaccine justifies itself. Yet the accumulating data gives vaccine recipients considerable reassurance and, if confirmed, has broad implications for its rollout in parts of the world.
In Africa, for example, distributing a single dose of vaccine that can be stored in the refrigerator for months is by far the most practical option.
Johnson & Johnson’s at least temporarily shut down the only plant that makes usable batches of the vaccine. However, South Africa-based Aspen Pharmacare, preparing for supply in large quantities to the rest of the continent. only 13 percent Percentage of Africans were fully vaccinated and only 1 percent received a supplemental dose.
Johnson & Johnson vaccine billed. attractive option For communities with limited access to healthcare, including some in the United States, due to its ease of delivery and mild side effects. But it’s been a bumpy ride.
The shot seemed to have a weaker initial immune response, and the more people who had a single dose of the vaccine, breakthrough infectionsCompared to those who received two doses of Pfizer or Moderna with mRNA vaccines.
Federal health officials in the United States and South Africa in April Johnson & Johnson pauses its vaccine distribution as they review rare reports blood coagulation disorder in women. The reputation of the vaccine was never fully recovered, although both countries soon resumed use.
But some experts said the idea that the vaccine was insufficient is outdated.
[ad_2]
Source link